Effects of dermatan sulfate, a heparin cofactor II mediated thrombin inhibitor, on the endotoxin-induced disseminated intravascular coagulation model in the rat: Comparison with low-molecular weight heparin, nafamostat mesilate and argathroban

Japanese Journal of Pharmacology

Volumn 76, Issue 4, 1998, Pages 397-404

  Onaya, Junichi ^a   Kyogashima, Mamoru ^a   Sunose, Atsuko ^a   Miyauchi, Satoshi ^a   Mizuno, Syoji ^a   Horie, Katsuyuki ^a  

^a SEIKAGAKU CORPORATION   (Japan)

Author keywords

Dermatan sulfate; Disseminated intravascular coagulation; Endotoxin; Hemorrhagic tendency; Thrombin clotting time

Indexed keywords

ARGATROBAN; DERMATAN SULFATE; FIBRIN; FIBRINOGEN; HEPARIN COFACTOR II; LOW MOLECULAR WEIGHT HEPARIN; NAFAMSTAT MESILATE; PROTHROMBIN; THROMBIN; THROMBIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFECT; FIBRIN DEPOSITION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PROTHROMBIN TIME; RAT; THROMBIN TIME; THROMBOCYTE COUNT;

EID: 0031970712     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.76.397     Document Type: Article

References (24)

1. Linhardt RJ and Hileman RE: Dermatan sulfate as a potential therapeutic agent. Gen Pharmacol 26, 443-451 (1995)
2. Tollefsen DM, Pestka CA and Monafo WJ: Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 258, 6713-6716 (1983)
3. Dol F, Caranobe C, Dupouy D, Petitou M, Lormeau JC, Choay J, Sie P and Boneu B: Effects of increased sulfation of dermatan sulfate on its in vitro and in vivo pharmacological properties. Thromb Res 52, 153-164 (1988)
4. Hoppensteadt D, Walenga JM and Fareed J: Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin. Thromb Res 60, 191-200 (1990)
5. Santoro FM, Alvarez R and Fussi F: Pharmacological profile of a native dermatan sulfate. Thromb Res 67, 201-211 (1992)
6. Maggi A, Abbadini M, Pagella PG, Borowska A, Pangrazzi J and Donati MB: Antithrombotic properties of dermatan sulfate in a rat venous thrombosis model. Haemostasis 17, 329-335 (1987)
7. Abbadini M, Zhu GJ, Maggi A, Pangrazzi J, Donati MB and Mussoni L: Dermatan sulfate induces plasminogen activator release in the perfused rat hindquarter. Blood 70, 1858-1860 (1987)
8. Bazzoni G, Beltran-Nunez A, Mascellani G, Bianchini P, Dejana E and Del-Maschio A: Effect of heparin, dermatan sulfate, and related oligo-derivatives on human polymorpho-nuclear leukocyte functions. J Lab Clin Med 121, 268-275 (1993)
9. Cofrancesco E, Boschetti C, Leonardi P, Gianese F and Cortellaro M: Dermatan sulfate for the treatment of disseminated intravascular coagulation (DIC) in acute leukaemia: A randomised, heparin-controlled pilot study. Thromb Res 74, 65-75 (1994)
10. Agnelli G, Cosmi B, Filippo PD, Ranucci V, Veschi F, Longetti M, Renga C, Barzi F, Gianese F, Lupattelli L, Rinonapoli E and Nenci GG: A randomised, double-blind, placebo-controlled trial of dermatan sulfate for prevention of deep vein thrombosis in hip fracture. Thromb Haemostas 67, 203-208 (1992)
11. Ryan KE, Lane DA, Flynn A, Ireland H, Boisclair M, Shepperd J and Curtis JR: Antithrombotic properties of dermatan sulfate (MF701) in haemodialysis for chronic renal failure. Thromb Haemostas 68, 563-569 (1992)
12. Muller-Berghaus G: Pathophysiologic and biochemical events in disseminated intravascular coagulation: Dysregulation of procoagulant and anticoagulant pathway. Semin Thromb Hemost 15, 58-86 (1989)
13. Arai M, Yada T, Suzuki S and Kimata K: Isolation and characterization of type IX collagen-proteoglycan from the swarm rat chondrosarcoma. Biochim Biophys Acta 1117, 60-70 (1992)
14. Yoshikawa T, Furukawa Y, Murakami M, Takemura S and Kondo M: Experimental model of disseminated intravascular coagulation induced by sustained infusion of endotoxin. Res Exp Med 179, 223-228 (1981)
15. Hamano S, Kinukawa M, Komatsu H, Miyata H and Sakuragawa N: Effects of low molecular weight heparin (FR-860) on the experimental disseminated intravascular coagulation models. Folia Pharmacol Jpn (Nippon Yakurigaku Zasshi) 98, 53-62 (1991) (Abstr in English)
16. Koshiyama Y, Kobori A, Ogihara M, Yokomoto Y, Ohtani K, Shimamura K and Iwaki M: The effects of FUT-175 (nafamostat mesilate) on blood coagulation and experimental disseminated intravascular coagulation. Folia Pharmacol Jpn (Nippon Yakurigaku Zasshi) 90, 313-320 (1987) (Abstr in English)
17. Kawamura M, Terashita Z, Imura Y, Shino A and Nishikawa K: Inhibitory effect of TCV-309, a novel platelet activating factor (PAF) antagonist, on endotoxin-induced disseminated intravascular coagulation in rats: Possible role of PAF in tissue factor generation. Thromb Res 70, 281-293 (1993)
18. Holmer E, Soderberg K and Berggvist D: Heparin and its low molecular weight derivatives; anticoagulant and antithrombotic properties. Hemostasis 16, Suppl 2, 1-7 (1986)
19. Aoyama T, Ino Y, Ozeki M, Oda M, Sato T, Koshiyama Y, Suzuki S and Fujita M: Pharmacological studies of FUT-175, nafamstat mesilate. Inhibition of protease activity in vitro and in vivo experiments. Jpn J Pharmacol 35, 203-227 (1984)
20. Kikumoto R, Tamao Y, Tezuka T, Tonomura S, Hara H, Ninomiya K, Hijikata A and Okamoto S: Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N-[3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-L- arginyl]-2-piperidinecarboxylic acid. Biochemistry 23, 85-90 (1984)
21. Cofrancesco E, Colombi M, Gianese F and Cortellaro M: The effect dermatan sulfate on in vitro human plasma coagulation, platelet aggregation and βTG/PF4 release. Thromb Res 57, 405-414 (1990)
22. Hoppensteadt D, Walenga JM and Fareed J: Effect of dermatan sulfate and heparan sulfate on platelet activity compared to heparin. Semin Thromb Hemost 17, 60-64 (1991)
23. Bounameaux H, Marbet GA, Lammle B, Eichlisberger R and Duckert F: Comparison of thrombin time, activated partial thromboplastin time, and plasma heparin concentration, and analysis of the behavior of antithrombin III. Am J Clin Pathol 74, 68-73 (1980)
24. Blajchman MA, Young E and Ofosu FA: Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits. Ann NY Acad Sci 556, 245-254 (1989)